Psyched Wellness Announces Secured Term Loan
Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCID: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. (together the "Lenders") for an aggregate p
Cannabis, Santé, Psychédéliques, Producteurs de cannabis
2026-10-08 5:15 PM EDT | Psyched Wellness Ltd.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova Scotia
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - October 7, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that the Breast Health Research Unit (BHRU) at IWK Health has joined as the second Canadian site in its large multi-center observational data collection study to advan
Technologies, Biotechnologies, Soins de santé et hôpitaux, Santé
2026-10-08 10:01 AM EDT | Breathe BioMedical Inc.
LIS Technologies Inc. Announces Major Milestone with the Receipt of an Initial Shipment of Uranium Hexafluoride (UF6) to be Leveraged at its State-of-the-Art Demonstration Test Loop Facility
Oak Ridge, Tennessee--(Newsfile Corp. - October 8, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced a major developmental milestone with the acceptance of its initial shipment of UF₆ for the demonstration and optimization of its CRISLA-4G process at its Test Demonstration Facility in Oak Ridge, Tennessee. Building on LIST
Technologies, Mines et métaux, Énergie, Santé
2026-10-08 8:29 AM EDT | LIS Technologies Inc.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psyche
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-10-08 8:19 AM EDT | Rhelion Life Sciences Corp.
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted ne
Biotechnologies, Pharmaceutique, Santé
2026-10-08 8:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Granted Mexican Patent for Newest Product, VIVI Box
Highlights Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engagement with appliance manufacturers across America's premium refrigeration sector Patent term extends through Octobe
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-10-08 3:05 AM EDT | TempraMed Technologies Ltd.
Avatar Medical Receives CE Marking for Avatar Medical Vision, the First Software CE-Marked for Use with a Glasses-Free 3D Medical Display
Paris, France--(Newsfile Corp. - October 8, 2026) - Journées Francophones de Radiologie (JFR 2026) - 08 October, 2026 -- Avatar Medical, an award-winning company advancing medical imaging from visualization to clinical understanding, today announced CE Marking for Avatar Medical Vision, its software platform to visualize CT and MR images in 3D and VR for surgical planning and intervention, enabling commercialization in Europe.
2026-10-08 1:42 AM EDT | Avatar Medical Vision
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical developmen
Biotechnologies, Pharmaceutique, Santé
2026-10-07 2:37 PM EDT | Hemostemix Inc.
Edison Client Omantel Takes Double Honours at 2026 MEIRA Annual Conference and Awards
London, United Kingdom--(Newsfile Corp. - October 7, 2026) - Edison Group, the leading global investor relations and research firm, congratulates its client Oman Telecommunications Company (Omantel) on winning two awards at the 2026 MEIRA Annual Conference and Awards, held on 1 October at the Atlantis, The Royal, Palm Jumeirah, Dubai. Omantel (MSX: OTEL) was named Leading Corporate for Investor Relations, Oman, and Aisha Al Balushi, was awarded Best Investor Relations Professional, Oman
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-10-07 8:38 AM EDT | Edison Group
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova Scotia
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - October 7, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that the Breast Health Research Unit (BHRU) at IWK Health has joined as the second Canadian site in its large multi-center observational data collection study to advan
Technologies, Biotechnologies, Soins de santé et hôpitaux, Santé
2026-10-07 8:00 AM EDT | Breathe BioMedical Inc.
Restart Life Advances Licensed Intellectual Property Portfolio Toward Commercial Launch
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an update regarding the strategic trademark licensing agreement originally announced on March 14, 2025 and updated on May 15, 2026. Since the May update, the Company has continued to advance the commercialization of the licensed intellectual property ("IP"). Multiple brand and product concepts have
2026-10-07 6:00 AM EDT | Restart Life Sciences Corp.
Palindrome Pharma Launches in Canada to Unlock Access to High-Quality Biosimilar Medicines
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, today announced its launch in Canada, with a mission to broaden access to high-quality biologic therapies and contribute to a more sustainable Canadian healthcare system. As demand for biologic medicines continues to grow, biosimilars have an important role to play in creating greater choices for Canadians. Palindrome Pharma will work with global and C
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-10-07 12:30 AM EDT | Palindrome Pharma Inc.
Unbuzzd Wellness Inc. Announces Refiling of Amended and Restated Interim Financial Statements and MD&A
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd, announces that it has filed amended and restated unaudited condensed interim consolidated financial statements for the three and nine months ended April 30, 2026 and 2025 (the "Amended Financial Statements"), together with amended and restated management's discussion and analysis (the "Amended MD&A"). The
2026-10-06 9:57 PM EDT | Unbuzzd Wellness Inc.
Apptly Closes First Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the "Company") is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement offering (the "Offering"), issuing 5,811,600 units of the Company (the "Units") at a price equal to $0.125 per Unit (the "Offering Price") for aggregate gross proceeds of $726,450. Each Unit is co
2026-10-06 7:27 PM EDT | Apptly Health Technologies Corp.
Microbiome Labs Unveils Enhanced Online Ordering Experience and Rebrand Shaped by Practitioner and Customer Feedback
Franklinton, North Carolina--(Newsfile Corp. - October 6, 2026) - Microbiome Labs™, a leader in spore-based probiotics and a division of Novonesis, announced the completion of a company-wide rebranding. Alongside this rebrand, the company launched a redesigned website and enhanced its online experience with capabilities that give practitioners a personalized way to provide education and recommend products directly to patients. These initiatives were unveiled to healthcare practitioners
2026-10-06 10:00 AM EDT | Microbiome Labs
Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million
Winter Park, Florida--(Newsfile Corp. - October 6, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has sold a 30% interest in Adia Labs LLC to Live Oak Health, a stem cell distributor doing business as QCM Biologics, for $1.5 million, and that the sale is paired with a distribution partnership. The Company has filed a Form 8-K related to the transaction. Link to Form 8-K here: Inline Viewer: ADIA MED, INC. 8-K 2026-
Soins de santé et hôpitaux, Santé
2026-10-06 9:20 AM EDT | Adia Med Inc.
Izotropic Closes Non-Brokered Private Placement
British Columbia and Casablanca, Morocco--(Newsfile Corp. - October 6, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that further to its September 25th announcement it has com
2026-10-06 8:00 AM EDT | Izotropic Corporation
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bi
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-10-06 7:00 AM EDT | Phio Pharmaceuticals Corp.
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt and Proposed Issuance of Shares as Payment of Accrued Director Fees
Burlington, Ontario--(Newsfile Corp. - October 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the "Notes"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on September 30, 2026. The Company expects to issue the Common Shares no later than
2026-10-05 8:37 AM EDT | Rapid Dose Therapeutics Corp.
Extendicare Announces Timing of 2026 Third Quarter Results and Conference Call
Markham, Ontario--(Newsfile Corp. - October 5, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced today that it plans to release its financial results for the third quarter of 2026 after market close on Thursday, November 5, 2026. A conference call hosted by Michael Guerriere, President and Chief Executive Officer and David Bacon, Executive Vice President and Chief Financial Officer, will be held on Friday, November 6, 2026, at 11:30 a.m. (EST) to discuss the
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-10-05 8:00 AM EDT | Extendicare Inc.